Skip to main content
. Author manuscript; available in PMC: 2014 Jun 30.
Published in final edited form as: J Bone Miner Res. 2013 Apr;28(4):865–874. doi: 10.1002/jbmr.1807

Fig. 6.

Fig. 6

Effect of unloading and sclerostin antibody treatment on serum sclerostin and markers of bone turnover. (A) Sclerostin (vehicle groups only); (B) Osteocalcin; (C) TRACP5b, and (D) CTX1. Horizontal bars designate significant differences between VEH and SclAbII within loading group (p < 0.05). †p < 0.01 CON versus HLU within a treatment group. Error bars represent 1 SEM.